Phase 1b trial assessing KT-621 in atopic dermatitis (AD) patients
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs KT 621 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- 21 Jan 2025 New trial record
- 14 Jan 2025 According to Kymera Therapeutics media release, Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis (AD) patients in 2Q25 with data in 4Q25